What is TR35 and why is it being researched for esophageal cancer treatment?

TR35 is an active fraction extracted from Xinjiang Bactrian camel milk. Research indicates that TR35 can inhibit the proliferation of esophageal cancer cells, specifically Eca109 cells, and induce apoptosis, or programmed cell death, in these cells. This makes TR35 a potential candidate for novel cancer treatments. Further research is needed to determine TR35's full therapeutic potential.

How does TR35 affect esophageal cancer cells in laboratory settings?

In in vitro experiments, TR35 has been shown to suppress the growth of Eca109 cells in a dose-dependent manner, meaning that higher concentrations of TR35 lead to a greater reduction in cancer cell growth. TR35 also induces apoptosis in these cells, which was confirmed through flow cytometry and nuclear morphology studies. These studies revealed nuclear fragmentation, a key indicator of apoptosis, in the cancer cells treated with TR35.

What molecular mechanisms are believed to be involved in TR35's anti-cancer effects?

Transcriptomic and proteomic analyses, including RNA-Seq and 2-DE combined with mass spectrometry, have identified differentially expressed genes and proteins in Eca109 cells treated with TR35. These analyses revealed a total of 405 differentially expressed genes and 55 differentially expressed proteins. Additionally, it was found that TR35 increases caspase-3 activity, a key enzyme in the apoptotic pathway, further supporting its role in triggering programmed cell death. These molecular changes suggest that TR35 influences various signaling pathways associated with cancer inhibition.

What are the next steps in researching the potential of camel milk and TR35 for cancer treatment?

Future research includes more in-depth in vivo experiments to study the effects of TR35 in living organisms. It also involves a thorough toxicity evaluation to ensure the safety of TR35 as a therapeutic agent. Another key area of investigation is identifying the specific proteins involved in the tumor-suppressing effects of TR35. These steps are crucial for translating the promising in vitro results into viable cancer treatments.

How does the discovery of TR35 connect with the historical use of camel milk and what are the broader implications for cancer treatment?

This discovery validates the traditional medicinal use of camel milk, suggesting that there are indeed active compounds with therapeutic potential within it. If TR35 or similar compounds prove effective and safe, it could lead to the development of a natural, effective therapy for esophageal cancer and potentially other types of cancer. The broader implications involve a shift towards exploring natural substances for cancer treatment, potentially offering new avenues for combating this disease with fewer side effects.

Illustration of TR35 targeting cancer cells. Camel milk compounds against cancer

Camel Milk's Secret Weapon: Unlocking Its Power Against Esophageal Cancer

Reese Marlowe in Health & Wellness December 2025 • 4 min read.

"New research reveals how a unique compound in camel milk could revolutionize cancer treatment."

Esophageal cancer, a formidable disease affecting millions worldwide, is characterized by its aggressive nature and limited treatment options. With survival rates remaining stubbornly low, the medical community is constantly seeking innovative approaches to combat this devastating illness. Recent studies have turned to the traditional medicinal properties of camel milk, revealing a potential breakthrough in cancer treatment.

This article delves into the groundbreaking research exploring the anti-cancer mechanisms of TR35, an active fraction derived from Xinjiang Bactrian camel milk. Through meticulous transcriptomic and proteomic analyses, scientists have uncovered the remarkable ability of TR35 to inhibit the proliferation of esophageal cancer cells and induce their apoptosis, offering a beacon of hope for patients and researchers alike.

Join us as we explore the science behind this exciting discovery, examining how TR35 interacts with cancer cells, the potential for future treatments, and the historical use of camel milk in traditional medicine. This research could lead to a new era of cancer treatment, with the prospect of a natural, effective therapy.

Unveiling TR35: The Active Compound in Camel Milk

Illustration of TR35 targeting cancer cells. Camel milk compounds against cancer

The study focuses on TR35, an active fraction extracted from Xinjiang Bactrian camel milk. The researchers aimed to understand how TR35 affects esophageal carcinoma cells, using in vitro and in vivo models. Their findings were remarkable: TR35 significantly inhibited the proliferation of Eca109 cells (a human esophageal cancer cell line) and triggered apoptosis, the programmed cell death that eliminates damaged or unwanted cells.

In the in vitro experiments, the researchers observed that TR35 effectively suppressed the growth of Eca109 cells in a dose-dependent manner. As the concentration of TR35 increased, the rate of cell proliferation decreased, demonstrating its potent anti-cancer activity. Moreover, the team found that TR35 induced apoptosis in these cancer cells. Using flow cytometry and nuclear morphology studies, they confirmed the presence of apoptotic cells, indicating that TR35 was indeed causing cancer cells to self-destruct.

MTT Assay: Demonstrated TR35's ability to inhibit cancer cell growth in a dose-dependent and time-dependent manner.
Apoptosis Assay: Revealed that TR35 treatment significantly increased the percentage of apoptotic cells, indicating its role in triggering programmed cell death.
Nuclear Morphology Study: Showed that TR35 treatment led to nuclear fragmentation, a hallmark of apoptosis.
Caspase-3 Activity: Identified that TR35 increased caspase-3 activity, which is a key enzyme in the apoptotic pathway.

To further investigate the mechanisms behind TR35's effects, the researchers conducted transcriptomic and proteomic analyses. RNA-Seq and 2-DE combined with mass spectrometry were used to identify differentially expressed genes and proteins in TR35-treated Eca109 cells. The results revealed a total of 405 differentially expressed genes and 55 differentially expressed proteins. Further analysis revealed signaling pathways associated with cancer inhibition, suggesting potential targets for therapeutic intervention.

Looking Ahead: The Future of Camel Milk in Cancer Treatment

The research on TR35 provides a promising foundation for future studies. The team's findings are a compelling reason to keep researching the potential of camel milk compounds. Future research includes further in-depth in vivo experiments, toxicity evaluation, and investigations into the specific proteins involved in the tumor-suppressing effects. The use of camel milk, a natural substance, could offer a new and effective approach to cancer treatment, making the fight against esophageal cancer more hopeful.